Page 1 | Search Results | ASH Clinical News | American Society of Hematology

1-20 of 174

Sort by

Sort Order Select

News

New Risk Classification Stratifies Outcomes in Older Intensively Treated Patients with AML

Lara C. Pullen, PhD

Abstract

View News titled, New Risk Classification Stratifies Outcomes in Older Intensively Treated Patients with AML

News

Weekly Low-Dose Regimen of Decitabine and Venetoclax as Effective as Higher Dose

Lara C. Pullen, PhD

Abstract

View News titled, Weekly Low-Dose Regimen of Decitabine and Venetoclax as Effective as Higher Dose

News

Addition of Induction Gilteritinib May Provide Some Benefit for Newly Diagnosed FLT3-Mutated AML

Leah Lawrence

Abstract

View News titled, Addition of Induction Gilteritinib May Provide Some Benefit for Newly Diagnosed FLT3-Mutated AML

News

Socioeconomic Factors, Education Levels Affect Access to AlloHCT

Lara C. Pullen, PhD

Abstract

View News titled, Socioeconomic Factors, Education Levels Affect Access to AlloHCT

News

Blinatumomab Added to Chemotherapy Is New Standard of Care in Newly Diagnosed Childhood SR B-ALL

Khylia Marshall

Abstract

View News titled, Blinatumomab Added to Chemotherapy Is New Standard of Care in Newly Diagnosed Childhood SR B-ALL

News

Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Respond Well to Asciminib, Dasatinib

Lara C. Pullen, PhD

Abstract

View News titled, Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Respond Well to Asciminib, Dasatinib

News

Venetoclax Effective for Bridging to Transplant in R/R AML, Study Suggests

Thomas R. Collins

Abstract

View News titled, Venetoclax Effective for Bridging to Transplant in R/R AML, Study Suggests

News

Genetics-Based Risk Model to Stratify Survival Outcomes of Patients With AML Treated With Venetoclax-Azacitidine

Anna Azvolinsky, PhD

Abstract

View News titled, Genetics-Based Risk Model to Stratify Survival Outcomes of Patients With AML Treated With Venetoclax-Azacitidine

News

Drawing First Blood: Will Menin Inhibitors Revolutionize the Treatment of AML?

Leah Lawrence

Abstract

View News titled, Drawing First Blood: Will Menin Inhibitors Revolutionize the Treatment of AML?

News

Study Examines Development of Paraparesis, Quadriparesis in Pediatric Patients With B-ALL Treated With CAR T-Cell Therapy

Anna Azvolinsky, PhD

Abstract

View News titled, Study Examines Development of Paraparesis, Quadriparesis in Pediatric Patients With B-ALL Treated With CAR T-Cell Therapy

News

Dose-Adjusted VEN-HMA Regimens Safe, Effective in Very Old Patients With AML

Leah Lawrence

Abstract

View News titled, Dose-Adjusted VEN-HMA Regimens Safe, Effective in Very Old Patients With AML

News

Straight-to-Transplantation Approach Comparable to Remission Induction in Difficult Acute Myeloid Leukemia Cases

Thomas R. Collins

Abstract

View News titled, Straight-to-Transplantation Approach Comparable to Remission Induction in Difficult Acute Myeloid Leukemia Cases

News

ATRA-ATO Regimen Demonstrates Superior EFS in Newly Diagnosed, High-Risk Acute Promyelocytic Leukemia

Khylia Marshall

Abstract

View News titled, ATRA-ATO Regimen Demonstrates Superior EFS in Newly Diagnosed, High-Risk Acute Promyelocytic Leukemia

News

Which Inhibitor Should Be Used to Treat FLT3-Positive AML?

Emma Yasinski

Abstract

View News titled, Which Inhibitor Should Be Used to Treat FLT3-Positive AML?

News

Efficacy of PTCy Raises Doubts About the Importance of HLA Matching in AlloHCT

Khylia Marshall

Abstract

View News titled, Efficacy of PTCy Raises Doubts About the Importance of HLA Matching in AlloHCT

News

Gilteritinib Effective for Post-Transplant Maintenance for Acute Myeloid Leukemia

Lara C. Pullen, PhD

Abstract

View News titled, Gilteritinib Effective for Post-Transplant Maintenance for Acute Myeloid Leukemia

News

FLT3-Mutated AML Responds Favorably to Triplet Regimen Including Inhibitor

Khylia Marshall

Abstract

View News titled, FLT3-Mutated AML Responds Favorably to Triplet Regimen Including Inhibitor

News

Molecular MRD Testing Identifies Patients with NPM1^mut AML Who May Benefit From Allogeneic Transplant

Lara C. Pullen, PhD

Abstract

View News titled, Molecular MRD Testing Identifies Patients with NPM1<sup>mut</sup> AML Who May Benefit From Allogeneic Transplant

News

Adults With Acute Myeloid Leukemia Follow One of Four Trajectories of Physical Well-Being

Lara C. Pullen, PhD

Abstract

View News titled, Adults With Acute Myeloid Leukemia Follow One of Four Trajectories of Physical Well-Being

News

Unique Molecular Subtypes within BCR::ABL1-Postive ALL Show Prognostic Relevance

Khylia Marshall

Abstract

View News titled, Unique Molecular Subtypes within BCR::ABL1-Postive ALL Show Prognostic Relevance

NARROW

New Risk Classification Stratifies Outcomes in Older Intensively Treated Patients with AML

Weekly Low-Dose Regimen of Decitabine and Venetoclax as Effective as Higher Dose

Addition of Induction Gilteritinib May Provide Some Benefit for Newly Diagnosed FLT3-Mutated AML

Socioeconomic Factors, Education Levels Affect Access to AlloHCT

Blinatumomab Added to Chemotherapy Is New Standard of Care in Newly Diagnosed Childhood SR B-ALL

Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Respond Well to Asciminib, Dasatinib

Venetoclax Effective for Bridging to Transplant in R/R AML, Study Suggests

Genetics-Based Risk Model to Stratify Survival Outcomes of Patients With AML Treated With Venetoclax-Azacitidine

Drawing First Blood: Will Menin Inhibitors Revolutionize the Treatment of AML?

Study Examines Development of Paraparesis, Quadriparesis in Pediatric Patients With B-ALL Treated With CAR T-Cell Therapy

Dose-Adjusted VEN-HMA Regimens Safe, Effective in Very Old Patients With AML

Straight-to-Transplantation Approach Comparable to Remission Induction in Difficult Acute Myeloid Leukemia Cases

ATRA-ATO Regimen Demonstrates Superior EFS in Newly Diagnosed, High-Risk Acute Promyelocytic Leukemia

Which Inhibitor Should Be Used to Treat FLT3-Positive AML?

Efficacy of PTCy Raises Doubts About the Importance of HLA Matching in AlloHCT

Gilteritinib Effective for Post-Transplant Maintenance for Acute Myeloid Leukemia

FLT3-Mutated AML Responds Favorably to Triplet Regimen Including Inhibitor

Molecular MRD Testing Identifies Patients with NPM1^mut AML Who May Benefit From Allogeneic Transplant

Adults With Acute Myeloid Leukemia Follow One of Four Trajectories of Physical Well-Being

Unique Molecular Subtypes within BCR::ABL1-Postive ALL Show Prognostic Relevance

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only